Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × capivasertib × Genitourinary × Clear all

Phase

Status

Completed 4 Active not recruiting 3 Recruiting 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Breast 1

Conditions

Adenocarcinoma of the Prostate 1

Interventions

Docetaxel 31 Radiosurgery 23 Radiotherapy 21 Sunitinib 20 pembrolizumab 18 Gemcitabine 17 Cisplatin 17 Androgen Antagonists 16 Nivolumab 14 enzalutamide 13 Surveys and Questionnaires 12 aldesleukin 11 Prednisone 11 Leuprolide 11 Goserelin 11 Cyclophosphamide 11 Blood Specimen Collection 11 Abiraterone Acetate 11 Carboplatin 10 Bevacizumab 10 bicalutamide 9 Multiparametric Magnetic Resonance Imaging 9 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8 Gonadotropin-Releasing Hormone 8 Filgrastim 8 Epirubicin 8 Chemotherapy, Adjuvant 8 Brachytherapy 8 toripalimab 7 tislelizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02525068 2018-08-08

RE-AKT

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡